<DOC>
	<DOC>NCT01925066</DOC>
	<brief_summary>The purpose of this study is to determine whether aerosolized vancomycin is effective in the treatment of methicillin-resistant staphylococcus aureus pneumonia under mechanical ventilation.</brief_summary>
	<brief_title>Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Pneumonia, Staphylococcal</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>Nosocomial or severe communityacquired pneumonia due to MethicillinResistant Staphylococcus aureus Must be mechanically ventilated in intensive care unit Nonbacterial pneumonia, such as viral, fungal, tuberculosis infections Underlying respiratory condition: bronchiectasis, posttuberculosis, chronic obstructive pulmonary disease or asthma Complicated pneumonia, such as empyema, parapneumonic effusion requiring chest tube or drainage Already or previous treated with intravenous vancomycin (Not pneumonia) Adverse reaction due to inhaled ventolin before treatment of aerosolized vancomycin Hypersensitivity of vancomycin or glycopeptide antibiotics Positive culture of Enterococcus in respiratory specimen Pregnant or Breastfeeding patient Immunocompromised hosts: more than 1mg/kg of corticosteroid users for more than 3 months, transplantation recipients, AIDS patients Another aerosolized antibiotics within 48 hours of study enrollment Not adherent to mechanical ventilation protocol of this study Not arterial line monitoring Vancomycin minimum inhibitory concentration &gt;= 2㎍/㎖ of cultured Staphylococcus aureus</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>